Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

CanAg Diagnostics

1992 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
Description

Developer of immunological reagents. The company develops monoclonal antibodies for the treatment of cancer, brain damage and tumors.

Website
Formerly Known As
Centocor Diagnostics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare
Acquirer
Fujirebio Diagnostics
Primary Office
  • Elof Lindälvs gata 13
  • 414 55 Gothenburg
  • Sweden
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore CanAg Diagnostics’s full profile, request a free trial.

CanAg Diagnostics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 31-May-2006 Completed Generating Revenue
2. Angel (individual) 01-Jan-2001 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

CanAg Diagnostics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Industrifonden Venture Capital Minority 000 0000 000000 0
Líftæknisjóðurinn MP BIO hf Venture Capital Minority 000 0000 000000 0

CanAg Diagnostics Executive Team (3)

Name Title Board
Seat
Contact
Info
Börje Karlsson Co-Founder
Leif Lindholm Co-Founder

1 Former Executive

You’re viewing 2 of 3 executives. Get the full list »